Table 3 Patient characteristics
Characteristic | 0.9% saline | Balanced/buffered fluid |
|---|---|---|
(n = ) | (n = ) | |
Country of enrollment, n (%) | ||
USA | ||
Canada | ||
Australia/New Zealand | ||
Age in years, median (IQR) | ||
Age category, n (%) | ||
6 mos to < 1 year | ||
1 year to < 5 years | ||
5 years to < 12 years | ||
12 years to < 18 years | ||
Sex, n (%) | ||
Male | ||
Female | ||
Other/unknown | ||
Race, n (%) | ||
White | ||
Black | ||
Asian | ||
American Indian/Alaska Native | ||
Native Hawaiian/Other Pacific Islander | ||
Unknown/not reporteda | ||
Ethnicity, n (%) | ||
Hispanic or Latino | ||
Aboriginal or Torres Strait Islander | ||
Maori | ||
Otherb | ||
Unknown/not reporteda | ||
Weight (kg), median (IQR) | ||
Comorbid conditions, n (%) | ||
Cancer (hematogenous or solid tumor) | ||
Bone marrow or solid organ transplant | ||
Cardiomyopathy or heart failure | ||
Pulmonary hypertension | ||
Kidney disease (not on dialysis) | ||
Neurologic dysfunction causing severe developmental delay | ||
Sickle cell disease | ||
Chronic ventilator dependence | ||
Indwelling central line | ||
Site of infection, n (%) | ||
Primary bloodstream | ||
Pneumonia or other lung infections | ||
Abdominal | ||
Genitourinary | ||
Central nervous system | ||
Skin/soft tissue | ||
Other infection | ||
Unknown site | ||
Alternative diagnosis (not infection) | ||
Positive blood culture (bacteremia) as either primary or additional site of infection, n (%) | ||
Concurrent Therapies (through study day 1, 11:59 pm) | ||
Antibiotics prior to study site ED arrival, n (%) | ||
Minutes to first antibiotic administration after ED arrival, median (IQR)c | ||
Ceftriaxone, n (%) | ||
Vasoactives, n (%) | ||
Corticosteroids, n (%) | ||
Bicarbonate or other buffers, n (%) | ||
Invasive mechanical ventilationd, n (%) | ||
Extracorporeal membrane oxygenation, n (%) | ||
Baseline creatinine (mg/dL)e, median (IQR) | ||
KDIGO acute kidney injury stage at enrollment, n (%) | ||
Stage 1 | ||
Stage 2 | ||
Stage 3 |